BioXcel Therapeutics Launches “Boiling Point” Educational Campaign to Shed Light on the Importance of Prompt and Cooperat...
April 29 2021 - 7:00AM
BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq:
BTAI), a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology, today announced the
launch of its “Boiling Point” Campaign to educate emergency medical
and psychiatric professionals on the full spectrum and severity of
agitation symptoms and the importance of a prompt, non-invasive
approach to care for patients with schizophrenia and bipolar
disorders.
Agitation is a common and difficult-to-manage symptom associated
with schizophrenia and bipolar disorders I and II1 that affects
more than 3 million people in the US each year. These patients can
experience, on average, a dozen agitation episodes annually that
require treatment.2 When agitation reaches severe levels, coercive
restraint and sedation are still used as intervention tactics for
up to 30 percent of patients.3 These tactics can contribute to the
worsening of symptoms, increasingly violent or aggressive behavior,
and a potentially dangerous care environment for patients and
healthcare providers alike.3 As such, prompt identification and
cooperative de-escalation of the initial behavioral and mental
signs of agitation are critical to preventing the emergence of
aggressive or violent behavior.4
“Acute agitation symptoms may manifest with various signs and
symptoms that can develop and change depending on the severity of a
patient’s agitation. Unfortunately, healthcare providers,
particularly in the emergency setting, usually identify agitation
when it’s reached a severe level and they need to take acute
measures to protect both patients and staff,” said Leslie Zun, MD,
MBA, Chairman, Department of Emergency Medicine, Professor of
Emergency Medicine, Rosalind Franklin University. “Educating
emergency medical and psychiatric professionals on the importance
of early identification and intervention around key symptoms – such
as poor impulse control, tension, hostility, uncooperativeness, and
excitement – will afford them the opportunity to intervene with
verbal de-escalation techniques and medication in order to work
collaboratively with patients before the agitation gets out of
hand.”
The focal point for the Campaign, www.PartnersInCalm.com, was
launched this Mental Health Awareness Month to arm healthcare
providers with the knowledge to promptly identify the signs of
agitation and learn about cooperative de-escalation techniques.
Importantly, the site offers healthcare providers tools and
resources on the observable behaviors of acute agitation as they
evolve from mild to severe. They can also review clinical
perspectives from experts on the unmet needs and best practices for
noncoercive treatment in hopes of easing the burden of care for
patients and healthcare providers.
“This campaign brings us one step closer to advancing the
management of acute agitation associated with neuropsychiatric
disorders by providing emergency room staff and other healthcare
providers with education and relevant resources they need to adopt
cooperative, patient-centric approaches for the treatment of
agitation,” said Will Kane, Chief Commercial Officer of
BioXcel.
For additional resources and campaign-related information,
please visit www.PartnersInCalm.com.
BioXcel Therapeutics, Inc.BioXcel Therapeutics,
Inc. is a clinical-stage biopharmaceutical company utilizing
artificial intelligence approaches to develop transformative
medicines in neuroscience and immuno-oncology. BioXcel's drug
re-innovation approach leverages existing approved drugs and/or
clinically validated product candidates together with big data and
proprietary machine learning algorithms to identify new therapeutic
indices. BioXcel's two most advanced clinical development programs
are BXCL501, an investigational, proprietary, orally dissolving
thin film formulation of dexmedetomidine for the treatment of
agitation and opioid withdrawal symptoms, and BXCL701, an
investigational, orally administered, systemic innate immunity
activator in development for the treatment of aggressive forms of
prostate cancer and advanced solid tumors that are refractory or
treatment naïve to checkpoint inhibitors. For more information,
please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics, Inc.www.bioxceltherapeutics.com
Media:
Diana Barduskdiana.bardusk@hellommc.com 1.929.294.0526
1 Martinez-Raga et al. 1st International Experts’ Meeting on
Agitation: Conclusions Regarding the Current and Ideal Management
Paradigm of Agitation. Front. Psychiatry (2018) 9:54. doi:
10.3389/fpsyt.2018.00054. 2 Roberts et al. Characterizing the
experience of agitation in patients with bipolar disorder and
schizophrenia. BMC Psychiatry (2018) 18:104.
https://doi.org/10.1186/s12888-018-1673-3.3 Gaynes et al.
Preventing and De-escalating Aggressive Behavior Among Adult
Psychiatric Patients: A Systematic Review of the Evidence. PS in
Advance (2017) 68(8), 819-831.
https://doi.org/10.1176/appi.ps.201600314.4 Richmond et al. Verbal
De-escalation of the Agitated Patient: Consensus Statement of the
American Association for Emergency Psychiatry Project BETA
De-escalation Workgroup. The western journal of emergency medicine
(2012) 13(1): 17-25. doi: 10.5811/westjem.2011.9.6864.
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioXcel Therapeutics (NASDAQ:BTAI)
Historical Stock Chart
From Sep 2023 to Sep 2024